| BORTEZOMIB | Small molecule | Mantle cell lymphoma | 26S proteosome inhibitor | 3.0 | Unknown status | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | breast cancer | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | bladder transitional cell carcinoma | 26S proteosome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IXAZOMIB | Small molecule | acute lymphoblastic leukemia | 26S proteasome inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 4.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | MALT lymphoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | Mantle cell lymphoma | 26S proteosome inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | amyloidosis | 26S proteosome inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | lung cancer | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | chronic graft versus host disease | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | small cell lung carcinoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | primary peritoneal carcinoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | head and neck malignant neoplasia | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| IXAZOMIB | Small molecule | neoplasm | 26S proteasome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | multiple myeloma | 26S proteosome inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | AL amyloidosis | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | prostate cancer | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | Splenic Marginal Zone Lymphoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | nodal marginal zone B-cell lymphoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | acute myeloid leukemia | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | AL amyloidosis | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 3.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | graft versus host disease | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | multiple myeloma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | multiple myeloma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | amyloidosis | 26S proteosome inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | unspecified peripheral T-cell lymphoma | 26S proteosome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| OPROZOMIB | Small molecule | neoplasm | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | uremia | 26S proteosome inhibitor | 1.0 | Unknown status | ClinicalTrials |
| BORTEZOMIB | Small molecule | Mantle cell lymphoma | 26S proteosome inhibitor | 4.0 | - | DailyMed |
| BORTEZOMIB | Small molecule | lung cancer | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | MALT lymphoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| MARIZOMIB | Small molecule | glioblastoma multiforme | 20S proteosome inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | glioma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | Mantle cell lymphoma | 26S proteosome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | classic Hodgkin lymphoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | neoplasm of mature B-cells | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | nasopharyngeal neoplasm | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | nodal marginal zone B-cell lymphoma | 26S proteosome inhibitor | 1.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 0.5 | Unknown status | ClinicalTrials |
| CARFILZOMIB | Protein | Waldenstrom macroglobulinemia | 26S proteosome inhibitor | 3.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | amyloidosis | 26S proteosome inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | fallopian tube cancer | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| MARIZOMIB | Small molecule | anaplastic ependymoma | 20S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | AL amyloidosis | 26S proteosome inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IXAZOMIB | Small molecule | lymphoblastic lymphoma | 26S proteasome inhibitor | 1.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | chronic graft versus host disease | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | non-small cell lung carcinoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | non-small cell lung carcinoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| IXAZOMIB | Small molecule | autoimmune thrombocytopenic purpura | 26S proteasome inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | leukemia | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| IXAZOMIB | Small molecule | multiple myeloma | 26S proteasome inhibitor | 4.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | Waldenstrom macroglobulinemia | 26S proteosome inhibitor | 4.0 | Unknown status | ClinicalTrials |
| BORTEZOMIB | Small molecule | non-small cell lung carcinoma | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | neoplasm | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 4.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | non-small cell lung carcinoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | Waldenstrom macroglobulinemia | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | salivary gland adenoid cystic carcinoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | urethra cancer | 26S proteosome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | plasmacytoma | 26S proteosome inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IXAZOMIB | Small molecule | follicular lymphoma | 26S proteasome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | neoplasm | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | nodal marginal zone B-cell lymphoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| MARIZOMIB | Small molecule | glioblastoma multiforme | 20S proteosome inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IXAZOMIB | Small molecule | multiple myeloma | 26S proteasome inhibitor | 1.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 0.5 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | Central Nervous System Neoplasm | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | gliosarcoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | amyloidosis | 26S proteosome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | chronic lymphocytic leukemia | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | ovarian cancer | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| IXAZOMIB | Small molecule | multiple myeloma | 26S proteasome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 2.0 | Unknown status | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 4.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | neuroendocrine carcinoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| IXAZOMIB | Small molecule | leukemia | 26S proteasome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | plasma cell leukemia | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | Mantle cell lymphoma | 26S proteosome inhibitor | 3.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | acute lymphoblastic leukemia | 26S proteosome inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | bronchoalveolar adenocarcinoma | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| CARFILZOMIB | Protein | lymphoma | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | MALT lymphoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | neuroblastoma | 26S proteosome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | chronic lymphocytic leukemia | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | autoimmune thrombocytopenic purpura | 26S proteosome inhibitor | 2.0 | Unknown status | ClinicalTrials |
| BORTEZOMIB | Small molecule | acute lymphoblastic leukemia | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| IXAZOMIB | Small molecule | AL amyloidosis | 26S proteasome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | melanoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | multiple myeloma | 26S proteosome inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | asymptomatic myeloma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | Mantle cell lymphoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| CARFILZOMIB | Protein | Mantle cell lymphoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | glioblastoma multiforme | 26S proteosome inhibitor | 0.5 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | intrahepatic cholangiocarcinoma | 26S proteosome inhibitor | 3.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | squamous cell carcinoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | peritoneum cancer | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 1.0 | Unknown status | ClinicalTrials |
| IXAZOMIB | Small molecule | acute myeloid leukemia | 26S proteasome inhibitor | 1.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 4.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | adult T acute lymphoblastic leukemia | 26S proteosome inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | kidney cancer | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | chronic graft versus host disease | 26S proteosome inhibitor | 2.0 | Unknown status | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | non-Hodgkins lymphoma | 26S proteosome inhibitor | 3.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | diffuse large B-cell lymphoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | follicular lymphoma | 26S proteosome inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IXAZOMIB | Small molecule | lymphoma | 26S proteasome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | nasopharyngeal neoplasm | 26S proteosome inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | neuromyelitis optica | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | acute myeloid leukemia | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | sarcoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | bronchiolitis obliterans | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| CARFILZOMIB | Protein | cancer | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | follicular lymphoma | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| IXAZOMIB | Small molecule | multiple myeloma | 26S proteasome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| MARIZOMIB | Small molecule | multiple myeloma | 20S proteosome inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 3.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | non-Hodgkins lymphoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | autoimmune thrombocytopenic purpura | 26S proteosome inhibitor | 3.0 | Unknown status | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | Kidney Medullary Carcinoma | 26S proteosome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | Mantle cell lymphoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | prolymphocytic leukemia | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | anaplastic large cell lymphoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| IXAZOMIB | Small molecule | lymphoblastic lymphoma | 26S proteasome inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | acute myeloid leukemia | 26S proteosome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | acute myeloid leukemia | 26S proteosome inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | Kaposi's sarcoma | 26S proteosome inhibitor | 2.0 | Suspended | ClinicalTrials |
| IXAZOMIB | Small molecule | lymphoma | 26S proteasome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | graft versus host disease | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | plasmacytoma | 26S proteosome inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | childhood T acute lymphoblastic leukemia | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | acute lymphoblastic leukemia | 26S proteosome inhibitor | 1.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | diffuse large B-cell lymphoma | 26S proteosome inhibitor | 2.0 | Unknown status | ClinicalTrials |
| BORTEZOMIB | Small molecule | lymphoma | 26S proteosome inhibitor | 3.0 | Withdrawn | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | AL amyloidosis | 26S proteosome inhibitor | 1.0 | Recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 0.5 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | diffuse large B-cell lymphoma | 26S proteosome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | leukemia | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | gastric cancer | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | lymphoproliferative syndrome | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | lymphoma | 26S proteosome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | Japanese encephalitis | 26S proteosome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 3.0 | Unknown status | ClinicalTrials |
| BORTEZOMIB | Small molecule | plasma cell leukemia | 26S proteosome inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | acute myeloid leukemia | 26S proteosome inhibitor | 2.0 | Unknown status | ClinicalTrials |
| BORTEZOMIB | Small molecule | anaplastic oligodendroglioma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| IXAZOMIB | Small molecule | Kidney Medullary Carcinoma | 26S proteasome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | medullary thyroid gland carcinoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | Hodgkins lymphoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | colorectal carcinoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | cervical cancer | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | mycosis fungoides | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | plasmacytoma | 26S proteosome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | gliosarcoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | graft versus host disease | 26S proteosome inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | breast adenocarcinoma | 26S proteosome inhibitor | 1.0 | Recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | diffuse large B-cell lymphoma | 26S proteosome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | leukemia | 26S proteosome inhibitor | 1.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | lymphoid neoplasm | 26S proteosome inhibitor | 4.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | neoplasm of mature B-cells | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | acute promyelocytic leukemia | 26S proteosome inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IXAZOMIB | Small molecule | multiple myeloma | 26S proteasome inhibitor | 4.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 4.0 | Unknown status | ClinicalTrials |
| BORTEZOMIB | Small molecule | myelodysplastic syndrome | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | T-cell acute lymphoblastic leukemia | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | Mantle cell lymphoma | 26S proteosome inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | hematopoietic and lymphoid cell neoplasm | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | neoplasm | 26S proteosome inhibitor | 4.0 | - | ATC |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | plasmacytoma | 26S proteosome inhibitor | 1.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | AL amyloidosis | 26S proteosome inhibitor | 3.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | metastatic malignant neoplasm | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | neoplasm of mature T-cells or NK-cells | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| OPROZOMIB | Small molecule | hepatocellular carcinoma | 26S proteosome inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 3.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | glioblastoma multiforme | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | pancreatic ductal adenocarcinoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | cancer | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | myelodysplastic syndrome | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| IXAZOMIB | Small molecule | neoplasm | 26S proteasome inhibitor | 4.0 | - | ATC |
| BORTEZOMIB | Small molecule | Mantle cell lymphoma | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | small intestine cancer | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | ovarian cancer | 26S proteosome inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | Castleman disease | 26S proteosome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | neoplasm | 26S proteosome inhibitor | 4.0 | - | ATC |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IXAZOMIB | Small molecule | Mantle cell lymphoma | 26S proteasome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | follicular lymphoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | follicular lymphoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| IXAZOMIB | Small molecule | acute lymphoblastic leukemia | 26S proteasome inhibitor | 1.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | anaplastic astrocytoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | chronic myeloproliferative disorder | 26S proteosome inhibitor | 0.5 | Completed | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | lymphoblastic lymphoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | thrombotic thrombocytopenic purpura | 26S proteosome inhibitor | 4.0 | Not yet recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | unspecified peripheral T-cell lymphoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| IXAZOMIB | Small molecule | HIV infection | 26S proteasome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | lymphoid neoplasm | 26S proteosome inhibitor | 1.0 | Unknown status | ClinicalTrials |
| IXAZOMIB | Small molecule | multiple myeloma | 26S proteasome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | colorectal carcinoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| IXAZOMIB | Small molecule | chronic kidney disease | 26S proteasome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | neoplasm of mature B-cells | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 4.0 | - | DailyMed |
| BORTEZOMIB | Small molecule | AL amyloidosis | 26S proteosome inhibitor | 3.0 | Terminated | ClinicalTrials |
| IXAZOMIB | Small molecule | multiple myeloma | 26S proteasome inhibitor | 4.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | urinary bladder carcinoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 3.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | leukemia | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | cancer | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | primary systemic amyloidosis | 26S proteosome inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IXAZOMIB | Small molecule | renal cell carcinoma | 26S proteasome inhibitor | 1.0 | Terminated | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | multiple myeloma | 26S proteosome inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | neuroblastoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | papillary thyroid carcinoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| IXAZOMIB | Small molecule | multiple myeloma | 26S proteasome inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | T-cell acute lymphoblastic leukemia | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 4.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | lung cancer | 26S proteosome inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | primary systemic amyloidosis | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | chronic graft versus host disease | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | neoplasm | 26S proteosome inhibitor | 4.0 | - | ATC |
| BORTEZOMIB | Small molecule | follicular lymphoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| IXAZOMIB | Small molecule | AL amyloidosis | 26S proteasome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | refractory anemia with excess blasts | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | chronic kidney disease | 26S proteosome inhibitor | 3.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | adult acute lymphoblastic leukemia | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | diffuse large B-cell lymphoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | graft versus host disease | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | multiple myeloma | 26S proteosome inhibitor | 3.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | immune system disease | 26S proteosome inhibitor | 2.0 | Unknown status | ClinicalTrials |
| BORTEZOMIB | Small molecule | lymphoma | 26S proteosome inhibitor | 0.5 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | myeloid sarcoma | 26S proteosome inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | lymphoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| MARIZOMIB | Small molecule | multiple myeloma | 20S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | acute leukemia of ambiguous lineage | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 0.5 | Terminated | ClinicalTrials |
| CARFILZOMIB | Protein | plasma cell leukemia | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | non-Hodgkins lymphoma | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | lymphoblastic lymphoma | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | lymphoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 3.0 | Not yet recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | renal cell carcinoma | 26S proteosome inhibitor | 1.0 | Unknown status | ClinicalTrials |
| CARFILZOMIB | Protein | prostate cancer | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | childhood B acute lymphoblastic leukemia | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | multiple myeloma | 26S proteosome inhibitor | 4.0 | - | DailyMed |
| BORTEZOMIB | Small molecule | breast cancer | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | primary systemic amyloidosis | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | therapy related acute myeloid leukemia and myelodysplastic syndrome | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | myelodysplastic syndrome | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | follicular thyroid carcinoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| IXAZOMIB | Small molecule | multiple myeloma | 26S proteasome inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IXAZOMIB | Small molecule | mixed phenotype acute leukemia | 26S proteasome inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IXAZOMIB | Small molecule | Waldenstrom macroglobulinemia | 26S proteasome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | pure red-cell aplasia | 26S proteosome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | lymphoma | 26S proteosome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | lung cancer | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | acute lymphoblastic leukemia | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | breast carcinoma | 26S proteosome inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IXAZOMIB | Small molecule | Mantle cell lymphoma | 26S proteasome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | adult acute lymphoblastic leukemia | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | prostate cancer | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 3.0 | Recruiting | ClinicalTrials |
| OPROZOMIB | Small molecule | Waldenstrom macroglobulinemia | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | therapy related acute myeloid leukemia and myelodysplastic syndrome | 26S proteosome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | multiple myeloma | 26S proteosome inhibitor | 3.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | acute myeloid leukemia | 26S proteosome inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IXAZOMIB | Small molecule | multiple myeloma | 26S proteasome inhibitor | 2.0 | Completed | ClinicalTrials |
| IXAZOMIB | Small molecule | multiple myeloma | 26S proteasome inhibitor | 2.0 | Terminated | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | cancer | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | acute promyelocytic leukemia | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | prostate cancer | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | MALT lymphoma | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | lymphoma | 26S proteosome inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | primary systemic amyloidosis | 26S proteosome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | acute lymphoblastic leukemia | 26S proteosome inhibitor | 3.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | primary systemic amyloidosis | 26S proteosome inhibitor | 3.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | childhood T acute lymphoblastic leukemia | 26S proteosome inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | esophageal cancer | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | qualitative or quantitative defects of dysferlin | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | myelodysplastic syndrome | 26S proteosome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | non-Hodgkins lymphoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | Hodgkins lymphoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | gastric cancer | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | acute myeloid leukemia | 26S proteosome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | Burkitts lymphoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 1.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | diffuse large B-cell lymphoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | diffuse large B-cell lymphoma | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| IXAZOMIB | Small molecule | multiple myeloma | 26S proteasome inhibitor | 3.0 | Completed | ClinicalTrials |
| MARIZOMIB | Small molecule | lymphoma | 20S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| IXAZOMIB | Small molecule | multiple myeloma | 26S proteasome inhibitor | 2.0 | Unknown status | ClinicalTrials |
| OPROZOMIB | Small molecule | cancer | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| IXAZOMIB | Small molecule | cancer | 26S proteasome inhibitor | 1.0 | Completed | ClinicalTrials |
| OPROZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | plasma cell leukemia | 26S proteosome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | Mantle cell lymphoma | 26S proteosome inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | urinary bladder cancer | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| IXAZOMIB | Small molecule | lymphoma | 26S proteasome inhibitor | 1.0 | Completed | ClinicalTrials |
| IXAZOMIB | Small molecule | multiple myeloma | 26S proteasome inhibitor | 3.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | non-small cell lung carcinoma | 26S proteosome inhibitor | 1.0 | Unknown status | ClinicalTrials |
| IXAZOMIB | Small molecule | lupus nephritis | 26S proteasome inhibitor | 1.0 | Terminated | ClinicalTrials |
| CARFILZOMIB | Protein | Waldenstrom macroglobulinemia | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | Mantle cell lymphoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | amyloidosis | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | prostate carcinoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | chronic lymphocytic leukemia | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| IXAZOMIB | Small molecule | multiple myeloma | 26S proteasome inhibitor | 4.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | acute lymphoblastic leukemia | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | lymphoma | 26S proteosome inhibitor | 0.5 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | hepatocellular carcinoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | lymphoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | Waldenstrom macroglobulinemia | 26S proteosome inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | lymphoma | 26S proteosome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | multiple myeloma | 26S proteosome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | soft tissue sarcoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 2.0 | Unknown status | ClinicalTrials |
| BORTEZOMIB | Small molecule | Sezary's disease | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | ureter cancer | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | lung adenocarcinoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | lymphoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | acute lymphoblastic leukemia | 26S proteosome inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IXAZOMIB | Small molecule | Anemia, Hemolytic, Autoimmune | 26S proteasome inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | diffuse large B-cell lymphoma | 26S proteosome inhibitor | 3.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | AL amyloidosis | 26S proteosome inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IXAZOMIB | Small molecule | hematopoietic and lymphoid cell neoplasm | 26S proteasome inhibitor | 2.0 | Completed | ClinicalTrials |
| IXAZOMIB | Small molecule | acute myeloid leukemia | 26S proteasome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | diffuse large B-cell lymphoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | Waldenstrom macroglobulinemia | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | lymphoblastic lymphoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | Waldenstrom macroglobulinemia | 26S proteosome inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | multiple myeloma | 26S proteosome inhibitor | 2.0 | Unknown status | ClinicalTrials |
| CARFILZOMIB | Protein | non-Hodgkins lymphoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| MARIZOMIB | Small molecule | ependymoma | 20S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | lymphoblastic lymphoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | neoplasm | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| IXAZOMIB | Small molecule | triple-negative breast cancer | 26S proteasome inhibitor | 1.0 | Terminated | ClinicalTrials |
| CARFILZOMIB | Protein | follicular lymphoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| IXAZOMIB | Small molecule | AL amyloidosis | 26S proteasome inhibitor | 3.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | acute lymphoblastic leukemia | 26S proteosome inhibitor | 1.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | lymphoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | Sezary's disease | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| CARFILZOMIB | Protein | Hodgkins lymphoma | 26S proteosome inhibitor | 1.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | graft versus host disease | 26S proteosome inhibitor | 1.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | adult T-cell leukemia/lymphoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | Waldenstrom macroglobulinemia | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 1.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | lymphoid neoplasm | 26S proteosome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | Mantle cell lymphoma | 26S proteosome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | chronic myelogenous leukemia | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | mesothelioma | 26S proteosome inhibitor | 2.0 | Unknown status | ClinicalTrials |
| BORTEZOMIB | Small molecule | acquired hemophilia | 26S proteosome inhibitor | 2.0 | Unknown status | ClinicalTrials |
| BORTEZOMIB | Small molecule | renal pelvis/ureter urothelial carcinoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | acute lymphoblastic leukemia | 26S proteosome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | adenoid cystic carcinoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | plasmacytoma | 26S proteosome inhibitor | 3.0 | Unknown status | ClinicalTrials |
| BORTEZOMIB | Small molecule | Hodgkins lymphoma | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| CARFILZOMIB | Protein | metastatic malignant neoplasm | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| IXAZOMIB | Small molecule | AL amyloidosis | 26S proteasome inhibitor | 1.0 | Recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 3.0 | Not yet recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | B-cell acute lymphoblastic leukemia | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | leukemia | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | prostate adenocarcinoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | breast cancer | 26S proteosome inhibitor | 0.5 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | angioimmunoblastic T-cell lymphoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | Glycogen storage disease due to acid maltase deficiency | 26S proteosome inhibitor | 4.0 | Unknown status | ClinicalTrials |
| CARFILZOMIB | Protein | diffuse large B-cell lymphoma | 26S proteosome inhibitor | 1.0 | Recruiting | ClinicalTrials |
| OPROZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| IXAZOMIB | Small molecule | multiple myeloma | 26S proteasome inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | nodular sclerosis Hodgkin lymphoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| CARFILZOMIB | Protein | mycosis fungoides | 26S proteosome inhibitor | 1.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | chronic myelogenous leukemia | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | colorectal carcinoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | acute lymphoblastic leukemia | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| IXAZOMIB | Small molecule | multiple myeloma | 26S proteasome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 3.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | head and neck malignant neoplasia | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | lymphoma | 26S proteosome inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| CARFILZOMIB | Protein | mycosis fungoides | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | lymphoma | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | multiple myeloma | 26S proteosome inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | Waldenstrom macroglobulinemia | 26S proteosome inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | plasma cell leukemia | 26S proteosome inhibitor | 2.0 | Unknown status | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | mixed phenotype acute leukemia | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | Lymphoma, AIDS-Related | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | mesothelioma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | Waldenstrom macroglobulinemia | 26S proteosome inhibitor | 1.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | Mantle cell lymphoma | 26S proteosome inhibitor | 1.0 | Unknown status | ClinicalTrials |
| BORTEZOMIB | Small molecule | melanoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| IXAZOMIB | Small molecule | multiple myeloma | 26S proteasome inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | autoimmune thrombocytopenic purpura | 26S proteosome inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 4.0 | - | DailyMed |
| BORTEZOMIB | Small molecule | Waldenstrom macroglobulinemia | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | Waldenstrom macroglobulinemia | 26S proteosome inhibitor | 2.0 | Unknown status | ClinicalTrials |
| BORTEZOMIB | Small molecule | acute myeloid leukemia | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | lymphoma | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| CARFILZOMIB | Protein | multiple myeloma | 26S proteosome inhibitor | 2.0 | Enrolling by invitation | ClinicalTrials |
| BORTEZOMIB | Small molecule | non-Hodgkins lymphoma | 26S proteosome inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | Mantle cell lymphoma | 26S proteosome inhibitor | 2.0 | Unknown status | ClinicalTrials |
| CARFILZOMIB | Protein | kidney cancer | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | Hodgkins lymphoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | plasma cell leukemia | 26S proteosome inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | lymphoma | 26S proteosome inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 1.0 | Unknown status | ClinicalTrials |
| IXAZOMIB CITRATE | Small molecule | plasma cell leukemia | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | acute graft vs. host disease | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| IXAZOMIB | Small molecule | plasmacytoma | 26S proteasome inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| IXAZOMIB | Small molecule | multiple myeloma | 26S proteasome inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| BORTEZOMIB | Small molecule | myelodysplastic syndrome | 26S proteosome inhibitor | 1.0 | Unknown status | ClinicalTrials |
| MARIZOMIB | Small molecule | cancer | 20S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | unspecified peripheral T-cell lymphoma | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | leukemia | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | multiple myeloma | 26S proteosome inhibitor | 3.0 | Unknown status | ClinicalTrials |
| BORTEZOMIB | Small molecule | urethra cancer | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | neoplasm of mature B-cells | 26S proteosome inhibitor | 2.0 | Recruiting | ClinicalTrials |
| BORTEZOMIB | Small molecule | leukemia | 26S proteosome inhibitor | 0.5 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | pancreatic carcinoma | 26S proteosome inhibitor | 2.0 | Terminated | ClinicalTrials |
| BORTEZOMIB | Small molecule | non-Hodgkins lymphoma | 26S proteosome inhibitor | 1.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | myelodysplastic syndrome | 26S proteosome inhibitor | 2.0 | Completed | ClinicalTrials |
| BORTEZOMIB | Small molecule | AL amyloidosis | 26S proteosome inhibitor | 3.0 | Recruiting | ClinicalTrials |